All In Biotech

Drug Trial Radar · NCT07830758

Resmetirom in Patients With MASH and HFpEF

A Phase 1b, Multi-Center, Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Hepatic Pharmacodynamics of Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Heart Failure With Preserved Ejection Fraction (HFpEF)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Oct 16, 2026

Primary completion

Nov 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Madrigal Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Sep 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1b multicenter randomized double-blind placebo-controlled study evaluates the safety, tolerability and hepatic pharmacodynamic effects of resmetirom in adults with metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). Participants are randomized 2:1 to resmetirom or placebo for 24 weeks.

Conditions

  • MASH - Metabolic Dysfunction-Associated Steatohepatitis
  • Heart Failure With Preserved Ejection Fraction (HFPEF)

Interventions

  • ResmetiromDrug

    Resmetirom (80 mg or 100 mg orally once daily based on body weight)

  • PlaceboDrug

    Matching placebo orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: From first dose through End of Study follow-up (28 days after last dose)
  2. Incidence of treatment-emergent serious adverse events (SAES)Time frame: From first dose through End of Study follow-up (28 days after last dose)
  3. Change from baseline in physical examination findings assessed by investigator physical examinationTime frame: Baseline to Week 24
  4. Change from baseline in body temperatureTime frame: Baseline to Week 24
  5. Change from baseline resting heart rateTime frame: Baseline to Week 24
  6. Change from baseline in respiratory rateTime frame: Baseline to Week 24
  7. Change from baseline in seated systolic blood pressureTime frame: Baseline to Week 24
  8. Change from baseline in seated diastolic blood pressureTime frame: Baseline to Week 24
  9. Change from baseline in PR interval on 12-lead ECG in milliseconds (ms)Time frame: Baseline to Week 24
  10. Change from baseline in QRS interval on 12-lead ECG in milliseconds (ms)Time frame: Baseline to Week 24
  11. Change from baseline in heart rate on 12-lead ECG in beats per minute (bpm)Time frame: Baseline to Week 24
  12. Change from baseline in RR interval on 12-lead ECG in milliseconds (ms)Time frame: Baseline to Week 24
  13. Change from baseline in QT interval on 12-lead ECG in milliseconds (ms)Time frame: Baseline to Week 24
  14. Change from baseline in QT interval corrected using Bazett's formula (QTcB) in milliseconds (ms)Time frame: Baseline to Week 24
  15. Change from baseline in QT interval corrected using Fridericia's formula (QTcF) in milliseconds (ms)Time frame: Baseline to Week 24
  16. Number of participants with clinically significant abnormalities in hematology laboratory parametersTime frame: Baseline to Week 24
  17. Number of participants with clinically significant abnormalities in blood chemistry laboratory parametersTime frame: Baseline to Week 24
  18. Number of participants with clinically significant abnormalities in urinalysis parametersTime frame: Baseline to Week 24
  19. Percent change from baseline in liver fat content measured by MRI-Proton Density Fat Fraction (MRI-PDFF)Time frame: Baseline to Week 24

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Clinical Trials

    Peoria, Arizona · Recruiting

  • FOMAT - Clinicas Mi Salud

    Oxnard, California · Recruiting

  • Covenant Metabolic Specialist

    Fort Myers, Florida · Recruiting

  • Covenant Metabolic Specialist

    Riverview, Florida · Recruiting

  • Covenant Metabolic Specialist

    University Park, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.